- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06863337
Glukosemønster hos infertile kvinder, der modtager assisteret reproduktion ved hjælp af kontinuerlig glukoseovervågning
Glukosemønster hos infertile kvinder, der modtager assisteret reproduktion: En prospektiv undersøgelse ved hjælp af kontinuerlig glukoseovervågning
No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200233
- Shanghai Sixth People's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Informed consent and voluntary participation in this study;
- Age ≥ 18 years and ≤40 years old;
- Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
- The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.
Exclusion Criteria:
- Recent infections (excluding viral infections of the reproductive system such as HPV);
- Recent glucocorticoid treatment or chemotherapy;
- Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
- Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: wearing continuous glucose monitorings
Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days. Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days. In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean sensor glucose (MSG)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Mean of daily continuous 24-h blood glucose |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
time in tight range(3.9~7.8mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time below range (<3.9mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM. |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Time above range (>7.8mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Coefficient of variation (CV)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation divided by mean glucose level measured by CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Standard deviation (SD)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Standard deviation of blood glucose measurements during CGM |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of oocytes retrieved
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of oocytes obtained under ultrasound guidance |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Oocyte retrieval rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Number of MII oocytes
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
The number of metaphase II oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of MII oocytes
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of oocytes that have nuclear maturity at the time of injection |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Rate of high-quality embryos
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)
|
the proportion of Day 2 and Day 3 embryos with high score or grade |
Through study completion (during assisted reproductive treatment period,about 2 months)
|
|
Biochemical pregnancy rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat. |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Clinical pregnancy rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 6 months)
|
The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy |
Through study completion (during assisted reproductive treatment period,about 6 months)
|
|
Miscarriage rate
Tidsramme: Through study completion, about 1 year
|
The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy |
Through study completion, about 1 year
|
|
Live Birth Rate
Tidsramme: Through study completion, 18 months
|
The proportion of successful deliveries resulting in a live-born infant. |
Through study completion, 18 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 20250303
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .